Mitigating cardiovascular risk in type 2 diabeteswith antidiabetes drugs: A review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials

Diabetes Care

Volumn 40, Issue 7, 2017, Pages 821-831

  Kaul, Sanjay ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PLACEBO; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; BENZHYDRYL DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLUCOSIDE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL OUTCOME; CLINICAL RESEARCH; DRUG EFFICACY; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HUMAN; MAJOR ADVERSE CARDIAC EVENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; ANIMAL; CARDIOVASCULAR DISEASE; COMPLICATION; RISK FACTOR;

ANIMALS; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85021079251     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0291     Document Type: Review

References (37)

1. Michael Specter. The danger of science denial. Available from https://www.ted.com/talks/michael-specter-the-danger-of-science-denial. Accessed 13 May 2017
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med 2007;357:100]. N Engl J Med 2007;356:2457-2471
3. U.S. Food and Drug Administration. Guidance for industry: diabetes mellitusdevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Silver Spring, MD, 2008. Available from http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm071627 .pdf). Accessed 11 April 2017
4. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
5. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 SteeringCommittee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
6. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
7. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257
8. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER SteeringCommittee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
9. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
10. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REGOUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
11. U.S. Food and Drug Administration. JARDIANCE (empagliflozin) tablets, for oral use: highlights of prescribing information. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2016/204629s008lbl.pdf. Accessed 30 January 2017
12. U.S. Food and Drug Adminisration. FDA briefing document: Endocrine and Metabolic Drug AdvisoryCommittee Meeting, June 28, 2016. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf. Accessed 30 January 2017
13. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8:237-240
14. Kaul S. Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true? Circulation 2016;134:94-96
15. Perret-Guillaume C, Joly L, Benetos A. Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis 2009;52:6-10
16. Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med 1999;130:1005-1013
17. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334
18. Shurter A, Genter P, Ouyang D, Ipp E. Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities. Diabetes Res Clin Pract 2013;100: 362-367
19. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348: 383-393
20. Fitchett D, Zinman B, Wanner C, et al.; EMPAREG OUTCOME-trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME-trial. Eur Heart J 2016;37:1526-1534
21. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). ClinicalTrials.gov identifier NCT03057977. Available from https://clinicaltrials.gov/ct2/show/NCT03057977. Accessed 9 April 2017
22. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). ClinicalTrials.gov identifier NCT03057951. Available from https://clinicaltrials.gov/ct2/show/NCT03057951. Accessed 9 April 2017
23. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care 2016;39: 1108-1114
24. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114: 1788-1803
25. Kumarathurai P, AnholmC, Nielsen OW, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Cardiovasc Diabetol 2016;15: 105
26. Margulies KB, Hernandez AF, Redfield MM, et al.; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-508
27. Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19: 69-77
28. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
29. Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silentmyocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis fromthe Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010; 31:92-99
30. Zhang ZM, Rautaharju PM, Prineas RJ, et al. Race and sex differences in the incidence and prognostic significance of silentmyocardial infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2016;133:2141-2148
31. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
32. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
33. American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135
34. Diabetes Canada. Pharmacologic management of type 2 diabetes: November 2016 interim update. Available from http://guidelines.diabetes .ca/browse/chapter13-2016. Accessed 30 January 2017
35. Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes 2016;9: 504-512
36. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care 2016;39:738-742
37. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. London, European Medicines Society, 2012